

	Month (%)	Quarter (%)	1 Year (%)	2 Years (% p.a.)	3 Years (% p.a.)	Since Inception [^] (% p.a.)	Since Inception Cumulative [^] (%)
eInvest Better Future Fund (Managed Fund)	-0.8	0.9	-6.6	-1.6	6.8	7.0	29.2
S&P/ASX Small Ordinaries Accumulation Index	-3.7	-1.2	-8.0	-1.7	4.2	2.8	10.8
Value Added	2.9	2.1	1.4	0.1	2.6	4.2	18.4

[^]Inception date was 23 May 2019. Performance shown above are net of fees. Fund returns are calculated using net asset value per unit at the start and end of the specified period and do not reflect the brokerage or the bid ask spread that investors incur when buying and selling units on the ASX. Past performance is not a reliable indicator of future performance.

Overview

The benchmark fell 3.7% during February and gave back some of its gains from January as interest rate expectations increased following better than expected economic data. The fund was down 0.8% after fees, outperforming the benchmark by 2.9%.

Positive contributors to relative performance this month included AUB Group (+17.4%), Steadfast Group (+11.3%), Alpha HPA (+17.6%), Smartgroup (+13.1%) and Sims (+4.7%).

The key negative contributors to relative performance this month were Immutep (-18.6%), Integral Diagnostics (-14.1%) and Pexa Group (-2.5%).

Better Future Highlight

During the month, the first time analysis of the primary endpoints and secondary endpoints of Telix's Phase III Ziron trial was delivered to the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco. The results were presented by Associate Professor Brian Such, MD, Director of the Kidney Cancer Program at the UCLA Institute of Urologic Oncology, who was a Principal Investigator of the trial. The trial examined the utility of Telix's imaging product in detecting clear cell renal cell carcinoma (renal or kidney cancer). Existing imaging cannot reliably distinguish between benign or malignant renal masses. Telix's Ziron product is designed to address this and help physicians manage renal cancer. The current method of determining whether a renal mass is malignant is to conduct an invasive biopsy on the patient.

The primary and secondary endpoints of the trial were met and exceeded and the Ziron product is now well positioned to obtain US Food and Drug Administration approval likely early in 2024, with product launch expected soon after this. This product is Telix's second imaging product, with the company's first product, Illucix, being a game-changer for helping urologists detect and manage prostate cancer. It is expected that the Ziron renal cancer imaging product will also greatly assist urologists in detecting and treating renal cancer.

eInvest Better Future Fund (Managed Fund)

The aim of IMPQ is to grow the value of your investment over the long term by investing in companies predominantly outside the S&P/ASX Top 50 Index that conduct business taking into account environmental, social and governance ("ESG") considerations and/or businesses that are making a positive contribution to creating a better future. IMPQ seeks to provide a total return (after fees) that exceeds the S&P/ASX Small Ordinaries Accumulation Index.

Portfolio Manager

Damian Cottier

IMPQ FUM

\$39 million

Distribution Frequency

Annually (if any)


Fees

0.99% p.a. (incl of GST and RITC)
+ Performance fee

Inception Date


23 May 2019

Growth of \$100,000 Since Inception



Performance shown net of fees with distributions reinvested. Does not take into account any taxes payable by an investor. Past performance is not a reliable indication of future performance.

Portfolios Contribution to the UN Sustainable Development Goals



Fund Review

The benchmark fell 3.7% during February and gave back some of its gains from January as interest rate expectations increased following better than expected economic data. The fund was down 0.8% after fees, outperforming the benchmark by 2.9%.

While the February reporting season was, in general, lackluster, a number of portfolio companies delivered strong results which was a driver of the outperformance over the month.

Positive contributors to relative performance this month included AUB Group (+17.4%), Steadfast Group (+11.3%), Alpha HPA (+17.6%), Smartgroup (+13.1%) and Sims (+4.7%).

The key negative contributors to relative performance this month were Immutep (-18.6%), Integral Diagnostics (-14.1%) and Pexa Group (-8.8%).

The results for insurance brokers AUB Group and Steadfast benefited from higher insurance premiums as a result of the increasing incidence of climate-related perils claims for insurers. In addition, AUB's acquisition of the UK-based Tyser's group is performing better than expected. The Smartgroup result was better than feared and indicated that the new year had started better than expected.

The Sims result benefited from the markets for recycled scrap metal materials improving towards the end of last year. Management also managed cashflow extremely well in what was a challenging six month period for the business given volatile end markets.

Immutep was weaker despite there being no surprises from its result. The Integral Diagnostics result was significantly weaker than expected as COVID-related impacts on diagnostic imaging volumes continued longer than expected and COVID-related sick leave early in the half and inflation had an impact on costs. On a more positive note, the new year appears to be off to a stronger start than last half and we expect volumes to recover this year.

The PEXA result was weaker due to higher than expected investment associated with entry into the UK market. During the month, while visiting the UK we conducted meetings with four participants in the UK conveyancing market to better understand the progress that PEXA is making in the UK. We came away from the meetings with greater confidence in the opportunity that the UK presents for PEXA and the headway that it is making.

During the month, portfolio company Calix announced two interesting developments. Firstly, it announced that Innovate UK had awarded GBP5M to a project led by Windship Technology Ltd in partnership with Calix to demonstrate a novel route to zero carbon shipping. This involves combining renewably powered propulsion and a lime-based carbon capture solution for remaining emissions. Calix also announced a memorandum of understanding with Heirloom Carbon Technologies. The MOU relates to a proposed license agreement for the use of Calix's kiln technology in the Direct Air Capture technology that Heirloom is developing to permanently remove carbon dioxide from the atmosphere. The investors in Heirloom include entities associated with Bill Gates and Microsoft.

At month end, the portfolio held 44 stocks and cash of 7.8%.

At February end, the weighted average Perennial-derived Environmental, Social, Governance and Engagement ("ESGE") Score of the Fund was 7.3 which is 28% higher than the benchmark ESGE Score of 5.7.

Contact us



Level 27, 88 Phillip Street
Sydney NSW 2000



1300 420 094



invest@perennial.net.au



www.perennial.net.au

Issued by Perennial Value Management Limited (ABN 22 090 879 904, AFSL No. 247293) as the Investment Manager. The Responsible Entity is Perennial Investment Management Limited (ABN 13 108 747 637, AFSL No. 275101). Perennial Partners Limited (ABN 90 612 829 160) is a Corporate Authorised Representative (1293138) of Perennial Value Management Limited. Both the Investment Manager and Responsible Entity form part of Perennial Partners. This promotional statement is provided for information purposes only. Accordingly, reliance should not be placed on this promotional statement as the basis for making an investment, financial or other decision. This promotional statement does not take into account your investment objectives, particular needs or financial situation and is not intended to constitute advertising or advice of any kind and you should not construe the contents of promotional statement as legal, tax, investment or other advice. This promotional statement does not constitute an offer or inducement to engage in an investment activity nor does it form part of any offer documentation, offer or invitation to purchase, sell or subscribe for interests in any type of investment product or service. You should read and consider any relevant offer documentation applicable to any investment product or service and consider obtaining professional investment advice tailored to your specific circumstances before making any investment decision. While every effort has been made to ensure the information in this promotional statement is accurate; its accuracy, reliability or completeness is not guaranteed. Past performance is not a reliable indicator of future performance. Net performance is based on redemption price for the period and assumes that all distributions are reinvested. Fees indicated reflect the maximum applicable. The current relevant product disclosure statement and target market determination can be found on Perennial's website www.perennial.net.au. Use of the information on our website is governed by Australian law and is subject to the terms of use. No distribution of this material will be made in any jurisdiction where such distribution is not authorised or is unlawful.

ESG Activity

Our ESG activity during the month included:

- Calix appointed a female director, Alison Deans, to the board. We have been engaging with Calix on improving the gender diversity on the board for some time and are pleased to see a very strong appointment. Ms Deans is currently the chair of Cochlear and previously the CEO of Ebay Australia.
- Met with Arena REIT to discuss modern slavery, RAP, solar panels and Sustainability linked loans.
- Discussed gender diversity and ESG strategies with Perpetual.
- Attended meetings in London with global ESG teams at Citi and Morgan Stanley to discuss Inflation Reduction Act (IRA), cyber security, nature-based solutions and alternative energy technologies.
- We discussed ESG with Nanosonics including minimising the environmental footprint of products and modern slavery in the supply chain. The company is focused on measuring Scope 1, Scope 2 and Scope 3 emissions and a program in place to recycle the Trophon product at end of life.

Top 5 Portfolio Positions	IMPQ (%)	Index (%)
Telix Pharmaceuticals Ltd	5.2	0.7
Meridian Energy Ltd	4.9	0.0
Sims Ltd	4.7	1.1
Chorus Ltd	4.2	1.4
AUB Group Ltd	4.2	1.1



Portfolio Manager, Damian Cottier (right) and Co-Head of ESG & Equities Analyst, Emilie O'Neill (left)